JCO Oncol Pract 2022 Jan 07
Q and A: A New Standard of Care for Germline and/or Mutation Carriers With Early-Stage Breast Cancer.
Related Questions
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (February 5, 2022)
"Should the preferred adjuvant agent be olaparib or capecitabine or sequential use for germline BRCA1/2 mutated TNBC with residual disease after neoadjuvant chemotherapy?" Res...
Would you continue pembrolizumab? Would you introduce olaparib? If using both, how would you sequence?
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (February 18, 2022)
The rate of pathologic complete response with chemotherapy is higher in gBRCA1m and/or gBRCA2m carriers with TNBC than in nonmutation carriers. The results of the KEYNOTE-522 ...